Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Imugene ( (AU:IMU) ) has provided an update.
Imugene Limited has announced a new application for the quotation of securities on the Australian Securities Exchange (ASX). The company plans to quote 51,177,612 new securities, specifically Quoted Options expiring on March 30, 2026, at an exercise price of $0.43. This move could potentially enhance the company’s financial flexibility and support its ongoing research and development efforts in the immuno-oncology sector.
The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited operates in the biotechnology industry, focusing on the development of novel therapies that harness the immune system to treat cancer. The company is primarily engaged in advancing its pipeline of immuno-oncology products to address unmet needs in cancer treatment.
Average Trading Volume: 1,690,173
Technical Sentiment Signal: Sell
Current Market Cap: A$76.45M
See more insights into IMU stock on TipRanks’ Stock Analysis page.